Systemic VEGF-A neutralization ameliorates diet-induced metabolic dysfunction

Diabetes

Volumn 63, Issue 8, 2014, Pages 2656-2667

  Wu, Lindsay E ^a,b   Meoli, Christopher C ^a   Mangiafico, Salvatore P ^c   Fazakerley, Daniel J ^a   Cogger, Victoria C ^d   Mohamad, Mashani ^d,e   Pant, Himani ^a   Kang, Myung Jin ^b   Powter, Elizabeth ^f   Burchfield, James G ^a   Xirouchaki, Chrysovalantou E ^c   Mikolaizak, A Stefanie ^g   Stöckli, Jacqueline ^a   Kolumam, Ganesh ^h   Van Bruggen, Nicholas ^h   Gamble, Jennifer R ^f   Le Couteur, David G ^d   Cooney, Gregory J ^a   Andrikopoulos, Sofianos ^c   James, David E ^a,d  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^f CENTENARY INSTITUTE   (Australia)

^g NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^h GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSITY; ANIMAL FEED; ANIMALS; ANTIBODIES; DIETARY FATS; GLUCOSE; HOMEOSTASIS; IMMUNOGLOBULIN G; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; OBESITY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905046885     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1665     Document Type: Article

References (48)

1. Segerström L., Fuchs D, Bäckman U, Holmquist K., Christofferson R, Azarbayjani F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res 2006; 60:576-581
2. Claes F, Vandevelde W, Moons L., Tjwa M. Another angiogenesis-independent role for VEGF: SDF1-dependent cardiac repair via cardiac stem cells. Cardiovasc Res 2011; 91:369-370
3. Tjwa M, Luttun A, Autiero M., Carmeliet P. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 2003; 314:5-14
4. Hagberg CE, Falkevall A, Wang X., et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010; 464:917-921
5. Hagberg CE, Mehlem A, Falkevall A., et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 2012; 490:426-430
6. Lu X, Zheng Y. Comment on: Elias et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012; 61:1801-1813
7. Diabetes 2013; 62:e3
8. Elias I, Franckhauser S, Bosch F. Response to Comment on: Elias et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012; 61:1801-1813
9. Diabetes 2013; 62:e4
10. Yilmaz M, Hotamisligil GS Damned if you do, damned if you don't: the conundrum of adipose tissue vascularization. Cell Metab 2013; 17:7-9
11. Loebig M, Klement J, Schmoller A., et al. Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men. PLoS ONE 2010; 5:e12610
12. García de la Torre N, Rubio MA, Bordiú E, et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 2008; 93:4276-4281
13. Silha JV, Krsek M, Sucharda P., Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 2005; 29:1308-1314
14. Lu X, Ji Y, Zhang L., et al. Resistance to obesity by repression of VEGF gene expression through induction of brown-like adipocyte differentiation. Endocrinology 2012; 153:3123-3132
15. Sun K, Wernstedt Asterholm I, Kusminski CM, et al Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A 2012; 109:5874-5879
16. Sung HK, Doh KO, Son J.E., et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab 2013; 17:61-72
17. Elias I, Franckhauser S, Ferré T, et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012; 61:1801-1813
18. Mullican SE, Tomaru T, Gaddis C.A., Peed LC, Sundaram A, Lazar MA. A novel adipose-specific gene deletion model demonstrates potential pitfalls of existing methods. Mol Endocrinol 2013; 27:127-134
19. Elmasri H, Karaaslan C, Teper Y., et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009; 23:3865-3873
20. Gerber HP, Malik AK, Solar G.P., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417:954-958
21. Lee S, Chen TT, Barber C.L., et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130:691-703
22. Bråkenhielm E., Cao R, Gao B., et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res 2004; 94:1579-1588
23. Kolonin MG, Saha PK, Chan L, Pasqualini R., Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004; 10:625-632
24. Rupnick MA, Panigrahy D, Zhang C.Y., et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A 2002; 99:10730-10735
25. Liang WC, Wu X, Peale F.V., et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951-961
26. Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov 2010; 9:107-115
27. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 2007; 117:2362-2368
28. Bruce CR, Hoy AJ, Turner N, et al Overexpression of carnitine palmitoyl-transferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes 2009; 58:550-558
29. Hoehn KL, Hohnen-Behrens C, Cederberg A., et al. IRS1-independent defects define major nodes of insulin resistance. Cell Metab 2008; 7:421-433
30. Hoehn KL, Salmon AB, Hohnen-Behrens C, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci U S A 2009; 106: 17787-17792
31. Hoehn KL, Turner N, Swarbrick M.M., et al. Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. Cell Metab 2010; 11:70-76
32. Mangiafico SP, Lim SH, Neoh S, et al A primary defect in glucose production alone cannot induce glucose intolerance without defects in insulin secretion. J Endocrinol 2011; 210:335-347
33. Cogger VC, Svistounov D, Warren A., et al. Liver Aging and Pseudocapilla-rization in a Werner Syndrome Mouse Model. J Gerontol A Biol Sci Med Sci. 22 Oct 2013 [Epub ahead of print]
34. Fuh G, Wu P, Liang W.C., et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006; 281:6625-6631
35. Yang JC, Haworth L, Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434
36. Willett CG, Boucher Y, Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23:8136-8139
37. Finley SD, Engel-Stefanini MO, Imoukhuede P.I., Popel AS. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol 2011; 5: 193
38. Turner N, Kowalski GM, Leslie S.J., et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 2013; 56:1638-1648
39. Kraegen EW, Clark PW, Jenkins A.B., Daley EA, Chisholm DJ, Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991; 40:1397-1403
40. Lijnen HR, Scroyen I. Effect of vascular endothelial growth factor receptor 2 antagonism on adiposity in obese mice. J Mol Endocrinol 2013; 50:319-324
41. Carpenter B, Lin Y, Stoll S., Raffai RL, McCuskey R, Wang R. VEGF is crucial for the hepatic vascular development required for lipoprotein uptake. Development 2005; 132:3293-3303
42. Taniguchi CM, Finger EC, Krieg A.J., et al. Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat Med 2013; 19:1325-1330
43. Wei K, Piecewicz SM, McGinnis L.M., et al. A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat Med 2013; 19:1331-1337
44. Ng Y, Ramm G, Lopez J.A., James DE. Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytes. Cell Metab 2008; 7: 348-356
45. Standaert ML, Galloway L, Karnam P., Bandyopadhyay G, Moscat J, Farese RV Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. J Biol Chem 1997; 272:30075-30082
46. Choi SM, Tucker DF, Gross D.N., et al. Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway. Mol Cell Biol 2010; 30:5009-5020
47. Simmgen M, Knauf C, Lopez M., et al. Liver-specific deletion of insulin receptor substrate 2 does not impair hepatic glucose and lipid metabolism in mice. Diabetologia 2006; 49:552-561
48. Farrell GC, Teoh NC, McCuskey RS Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken) 2008; 291:684-692